This work provides evidence that serum retinoid concentrations are affected in HIV-infected adults and that both cART and HIV infection are contributing factors. An optimal cART and, to a lesser degree, a suboptimal cART, drastically diminished serum RAs concentrations in HIV-infected adults in comparison to healthy volunteers. This effect was more pronounced and statistically significant in patients with intensified and prolonged optimal cART. Longitudinal assessments in these patients while on or off cART did not show significant changes. This could be due to the low number of participants, great interindividual variability and mostly to the different duration of ON1 versus ON2 and OFF1 versus OFF2. However, if we look at the 75% percentile we see the same "pattern": RA levels increase during cART interruptions and diminish when cART is re-initiated. Decreased serum RA concentrations during cART is probably the result of altered intracellular retinoid metabolism by cART. We previously demonstrated that some antiretrovirals increase in vitro activity of RALDH1 and, consequently, RAs synthesis . Moreover, one protease inhibitor, indinavir, also augmented RALDH1 mRNA expression . In vivo, such antiretrovirals might also affect intracellular RALDH1, and increase intracellular RAs concentrations especially in those tissues actively involved in retinoid metabolism, like adipose tissue, in which they penetrate, and accumulate [24, 25]. However, not all PIs have the same effect since they enter and accumulate differently in different tissues and have different intracellular localizations [21, 25, 26]. Moreover, as it was recently reported, adipose tissue influences tissue distribution of carotenoids  and certainly of RAs . Heightened RAs concentrations in different tissues  enhance the expression of various P450 CYP enzymes such as CYP 26A1, CYP 26B1 and CYP 26C1, resulting in increased RAs catabolism [10, 27]. Of note, these CYP enzymes are different than those affected by PIs. Furthermore, elevated intracellular RAs concentrations have a negative feedback action and reduce their own synthesis by lowering RALDH1 expression . Therefore, it is likely that the low serum RAs concentrations in patients with optimal cART could be due to increased RAs catabolism and feedback inhibition of their synthesis that followed increases in their intracellular concentration when cART was initiated. In order to document this assumption, concomitant measurements of serum and tissue RAs concentrations are necessary. This was not possible when this study was undertaken because our technique was not suited, at that time, for tissue samples processing. Altered retinoid metabolism could have multiple consequences by affecting RAs-dependent genes involved in metabolic, hormonal and immune processes [4, 6, 1, 23] and may explain some reported HIV- and cART-related metabolic and hormonal abnormalities .
It was shown previously that retinoids can modulate HIV-1 long terminal repeat-directed expression and either augment or reduce HIV replication according to cell line and culture conditions [29, 30]. It was also reported that all-trans RA may act as a reverse transcriptase inhibitor reducing the HIV-1 proviral DNA load . In both our groups of HIV-infected persons, serum RAs concentrations were not correlated with viral load, or CD4+ T-cell count or CD8+ 38+ fluorescence index. However, such correlations might exist between intracellular RAs concentrations and viro- immunological results. It is noteworthy that in G1 patients, RAs were significantly correlated with fasting serum C-peptide when their cART was reinitiated after the first cART interruption. This is consistent with the reported correlation between RAs and hemoglobin A1c in diabetes mellitus patients .
We also showed that ROL concentrations were highest during intensified, optimal cART, and they decreased during cART interruptions when HIV load rebounded, and then increased slightly when cART was resumed and VL was again undetectable. We observed also that HIV-infected adults with suboptimal cART have significantly lower ROL concentrations than patients with optimal cART and healthy adults. These data confirm our previous results  and are in keeping with other reports [17–19]. These observations clearly underline the negative effect of HIV infection on serum ROL and the beneficial effects of optimal cART.
Decreased serum ROL concentrations have been noted in HIV-infected individuals since the beginning of the AIDS epidemic, and they have been correlated with HIV-related morbidity and mortality as well as mother-to-child HIV transmission [19, 33, 34]. In fact, it is well known that plasma ROL decreases during inflammation and infection, including HIV . In one study, patients with raised C-reactive protein levels had ROL concentrations lower by 25% . It is suggested, therefore, to adjust serum ROL measurements with the concomitant values of inflammatory markers, such as C-reactive protein, in order not to overestimate vitamin A deficiency . Although we routinely measure C-reactive protein levels in our HIV-infected patients, this was not included in the initial protocol. If we retrospectively adjust serum ROL levels during uncontrolled HIV infection by increasing the measured values by 25% for C-reactive protein elevation as suggested  we still have significant differences between G1 and G2.
Vitamin A supplementation has been shown, in some reports, to be beneficial in children, women and HIV-infected people in developing countries [29, 33, 34]. However, other reports showed that vitamin A and β-carotene supplementation in lactating women increases HIV load in breast milk . Furthermore, vitamin supplementation, including vitamin A and β-carotene, increases the risk of subclinical mastitis in HIV-infected women . A systematic review of randomized trials did not support vitamin A supplementation of HIV-infected pregnant and lactating women, despite improvement in birth weight . A Cochrane review also found that currently available evidence does not support the use of Vitamin A supplementation of HIV-infected pregnant women to reduce mother-to-child transmission of HIV . The best way to normalize or increase ROL levels is to optimally treat HIV infection as our data clearly showed.
The elevated ROL concentrations detected during optimal cART are certainly the result of appropriate control of HIV infection, and, probably, of improved epithelial integrity and increased intestinal absorption [10, 40, 41]. Decreased ROL utilization is also possible, due to decreased RAs synthesis. The ROL concentrations correlated with serum triglycerides and cholesterol in G1 while on cART, suggesting that both ROL elevation and these metabolic abnormalities are, partly, related to cART. Moreover, HIV-infected patients had significantly higher baseline triglycerides levels in comparison with healthy volunteers. Elevation of serum triglyceride concentrations is a known adverse effect of some antiretrovirals  and is also reported in patients treated with RA . This finding indirectly suggest that cART-related hypertriglyceridemia might be secondary to increased intracellular RA levels.
Finally, we observed that ROL/RAs ratios are significantly elevated during cART, especially during its intensification, as compared with healthy controls and people with suboptimally-controlled HIV infection. Both increased ROL and diminished RAs levels were responsible for such high ratios.
The limitations of this study should be also considered, mainly the reduced sample size and uneven gender distribution. We had only 10 participants in CTN 140 trial due to ethical requirements in 1999 when this clinical trial was designed, and only 12 consecutive patients with suboptimal cART when the cross-sectional assessments were performed. However, in spite of this small sample size, we demonstrated statistically significant differences between groups and intra subjects followed longitudinally. As to the gender, there are no clear data showing gender differences in retinoid metabolism . We did not find significant differences between healthy males and health females. When we analysed separately the male persons only, in spite of the reduced sample size of 10 patients in each group, we obtained similar results as for the whole group of participants.
HIV-infected persons were receiving different cART regimens when the tests were performed and this might be another limitation. However, the study was not designed to assess the effects of different cART on serum retinoids but rather the effects of optimal versus suboptimal cART and of HIV alone during cART interruptions. Another limitation is the lack of a control group of naïve-to-treatment HIV-infected persons. This was not possible when this exploratory study was initiated because very few naïve patients were seen at our center and most of them were hospitalised for AIDS-related illnesses. Furthermore, the effects, if any, of therapeutic vaccination and hydroxyurea (used to diminish the lymphocyte activation) could not be totally excluded. However, the intra-subject approach with longitudinal assessments diminished this theoretical bias. Moreover, hydroxyurea has a short half-life and is was given as a single dose in the evening and the blood specimens for retinoid assessments were drawn more than12 hours after the dose. Finally, being an exploratory work we did not assessed concomitant intracellular retinoid levels.
Nevertheless, we demonstrate that serum retinoids are significantly altered in adults with chronic HIV infection and that the contributing factors could be both HIV infection and its treatment. Based on these data and previous in vitro work we may assume that some of the retinoid-like side-effects, including metabolic abnormalities or clinical events, seen in HIV-infected persons on cART are due, at least in part, to altered intracellular retinoid metabolism . Moreover, other beneficial non-virologic effects of antiretrovirals might be related to the effects of cART on retinoid metabolism . However, further studies assessing concomitant serum and intracellular retinoid levels during different cART regimens in larger, homogenous groups of HIV-infected persons are warranted.